Macquarie Group Ltd. decreased its holdings in Amedisys Inc (NASDAQ:AMED) by 2.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,253 shares of the health services provider’s stock after selling 482 shares during the period. Macquarie Group Ltd. owned approximately 0.06% of Amedisys worth $2,338,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in AMED. Price T Rowe Associates Inc. MD raised its holdings in Amedisys by 286.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,349,405 shares of the health services provider’s stock valued at $163,831,000 after acquiring an additional 999,892 shares during the last quarter. William Blair Investment Management LLC raised its holdings in Amedisys by 937.5% in the 2nd quarter. William Blair Investment Management LLC now owns 988,533 shares of the health services provider’s stock valued at $120,018,000 after acquiring an additional 893,253 shares during the last quarter. Riverbridge Partners LLC acquired a new stake in Amedisys in the 2nd quarter valued at about $80,465,000. Eagle Asset Management Inc. acquired a new stake in Amedisys in the 2nd quarter valued at about $35,359,000. Finally, Nuveen Asset Management LLC raised its holdings in Amedisys by 2,107.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 261,108 shares of the health services provider’s stock valued at $31,702,000 after acquiring an additional 249,280 shares during the last quarter. Institutional investors own 88.53% of the company’s stock.
Shares of NASDAQ AMED opened at $130.03 on Friday. The company has a 50 day simple moving average of $130.34 and a 200-day simple moving average of $124.53. The company has a market capitalization of $4.04 billion, a P/E ratio of 30.03, a P/E/G ratio of 1.87 and a beta of 1.44. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.88 and a quick ratio of 0.88. Amedisys Inc has a 1 year low of $97.38 and a 1 year high of $141.98.
A number of analysts have commented on the stock. Raymond James increased their price objective on shares of Amedisys from $140.00 to $144.00 and gave the company an “outperform” rating in a report on Monday, July 15th. Barclays increased their price objective on shares of Amedisys from $120.00 to $125.00 and gave the company an “equal weight” rating in a report on Monday, August 5th. ValuEngine downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a report on Thursday, September 26th. BidaskClub upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a report on Friday, July 26th. Finally, Deutsche Bank assumed coverage on shares of Amedisys in a report on Monday, September 16th. They issued a “buy” rating and a $155.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Amedisys presently has an average rating of “Buy” and a consensus target price of $141.51.
In related news, COO Christopher Gerard sold 350 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $134.79, for a total transaction of $47,176.50. Following the completion of the transaction, the chief operating officer now owns 25,381 shares of the company’s stock, valued at approximately $3,421,104.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sharon Brunecz sold 1,050 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $136.28, for a total transaction of $143,094.00. Following the transaction, the insider now directly owns 11,480 shares of the company’s stock, valued at approximately $1,564,494.40. The disclosure for this sale can be found here. Insiders have sold a total of 23,099 shares of company stock valued at $3,031,888 in the last 90 days. Insiders own 2.90% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Story: Net Asset Value
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.